11.15USD+1.60%Mkt Cap: 698.27M USDP/E: —Last update: 2026-05-26
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The compa…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap698.27M USD
Enterprise Value467.56M USD
Revenue (TTM)—
Gross Profit-58.13M USD
Net Income (TTM)-69.79M USD
Revenue/Share—
Last Price11.15 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees54
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.73
PEG—
EV/EBITDA-6.01
EV/Revenue—
P/S—
P/B3.15
EPS (TTM)-1.20
EPS (Forward)-1.64
52W Range
3.33056% of range17.25
52W High17.25 USD
52W Low3.330 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.84%
ROA-30.85%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-54.36M USD
CapEx (TTM)193.00K USD
FCF Margin—
FCF Yield-4.52%
Net Debt-220.09M USD
Net Debt/EBITDA2.83
Balance Sheet
Debt/Equity0.01
Current Ratio22.28
Quick Ratio22.05
Book Value/Sh3.492 USD
Cash/Share3.568 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)21.00 USD
Target Range20.00 USD – 22.00 USD
# Analysts6
Ownership
Shares Out.62.46M
Float35.36M
Insiders31.93%
Institutions61.33%
Short Interest
Short Ratio4.9d
Short % Float4.93%
Short % Out.3.72%
Shares Short2.32M
Short (prev mo.)2.08M
Technical
SMA 5012.33 (-9.6%)
SMA 2009.050 (+23.2%)
Beta1.74
S&P 52W Chg28.31%
Avg Vol (30d)971.04K
Avg Vol (10d)1.67M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—